BioMarin to Highlight Breadth of Innovative Development Pipeline at R&D Day on April 20th in New York
April 18 2016 - 7:30AM
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) will host an R&D Day
from 8am (ET) to 12pm (ET) on Wednesday, April 20, 2016 in New York
City. BioMarin management and external experts will provide an
update to the investment community on the Company’s development
portfolio, which is focused on innovative therapies to treat rare
and ultra-rare diseases.
Specifically, the BioMarin leadership team will
highlight:
- Preliminary data from BMN 270 (gene therapy) trial in
Hemophilia A
- A review of cerliponase alfa for CLN2, a form of Batten
Disease
- A review of pegvaliase for phenylketonuria (PKU)
- One year data with vosoritide for Achondroplasia
BioMarin speakers scheduled to present include:
Jean-Jacques Bienaimé, Chairman and Chief Executive
OfficerHank Fuchs, M.D., Executive Vice President and Chief Medical
OfficerWolfgang Dummer, M.D., Ph.D., Vice President, Clinical
DevelopmentSarah Noonberg, M.D., Ph.D., Group Vice President, Head
of Global Clinical DevelopmentLen Post, Ph.D., Group Vice
President, Chief Scientific OfficerCamilla Simpson, M.Sc., Group
Vice President, Regulatory Affairs
External key opinion leaders scheduled to present
include:
Cary Harding, M.D., Professor of Molecular and
Medical Genetics and Pediatrics at Oregon Health and Science
University
- Lead investigator, pegvaliase pivotal study
John Pasi, Ph.D., Professor of Haemostasis and
Thrombosis, Barts and the London School of Medicine and Dentistry,
Queen Mary, University of London
- Lead investigator, BMN 270 phase 1/2 study
Ravi Savarirayan, M.D., Professor, Department of
Paediatrics, University of Melbourne
- Lead investigator, vosoritide phase 2 study
Live Video WebcastInterested
parties may access a live video webcast that will include audio and
slides of the presentations via the investor section of the
BioMarin website, www.BMRN.com. A replay of the meeting will
be archived on the site for at least one week.
For those who choose not to listen and view the
event via webcast, dial-in information for the audio portion of the
webcast can be accessed using:
U.S. / Canada Dial-in Number: (877) 303-6313
International Dial-in Number: (631) 813-4734 Conference ID:
93170415
About BioMarinBioMarin is a global
biotechnology company that develops and commercializes innovative
therapies for patients with serious and life-threatening rare and
ultra-rare genetic diseases. The company's portfolio consists of
five commercialized products and multiple clinical and pre-clinical
product candidates. For additional information, please
visit www.BMRN.com. Information on BioMarin's website is not
incorporated by reference into this press release.
Contacts:
Investors
Traci McCarty
BioMarin Pharmaceutical Inc.
(415) 455-7558
Media
Debra Charlesworth
BioMarin Pharmaceutical Inc.
(415) 455-7451
BioMarin Pharmaceutical (NASDAQ:BMRN)
Historical Stock Chart
From Apr 2024 to May 2024
BioMarin Pharmaceutical (NASDAQ:BMRN)
Historical Stock Chart
From May 2023 to May 2024